Preventive Medicine Leader Meiy年 Health Joins Health Growth Alliance to Tackle Precision Matching of Products and Channels in the Out-of-Hospital Market

[Editor’s Note] The landscape of the healthcare and wellness industry is undergoing rapid restructuring. As the focus shifts from a “hospital-centric” model to “collaboration between in-hospital and out-of-hospital settings,” a new product marketing ecosystem is accelerating its formation. Driven by top-down policy guidance and structural changes within the industry, this trend has become unstoppable. This past May, Li Datao, Founder of VCBeat; Wang Rui, Secretary-General of the Health Growth Society; and Yu Rong, Chairman of Meinian Onehealth Healthcare Holdings Co., Ltd. and Chairman of the Health Growth Society, jointly announced the official establishment of the Health Growth Society. On the upcoming June 20, the Health Growth Society will partner with Meinian Onehealth to launch the first session of its Practical Workshop on Commercial Growth Case Studies. Ahead of this inaugural workshop, VCBeat took the opportunity to speak with Yu Rong to gain insights into the development of the out-of-hospital market and ecosystem building from Meinian Onehealth’s perspective.

Why Should China’s Leading Preventive Medicine Company Join an Out-of-Hospital Market Ecosystem Driven by New Products, New Production, and New Channels?

In May this year, during the 2025 VBEF Future Medicine Top 100 Exhibition, the Health Growth Community, initiated by VCBeat, was officially established. Adhering to the mission of "precise connection, knowledge empowerment, and ecosystem collaboration,"Health Growth Society is core-oriented toward the demand for commercial growth outside hospitals, dedicated to bridging the “production (pharmaceutical companies/medical devices/health products) – sales (new channels)” link. It aims to build an ecosystem community for the out-of-hospital market driven by new products, new production models, and new channels, thereby facilitating efficient and precise matching between the most outstanding products in the pharmaceutical and healthcare industry and the leading new channels, jointly creating the largest commercial growth transaction platform for China’s healthcare sector.

The current chairman of the Healthy Growth Society is none other than Yu Rong, Chairman of Meinian Onehealth, the leading preventive medicine company in China. On an afternoon in June, VCBeat sat down for an interview with Yu Rong, seeking answers to the questions raised at the beginning of this article. From his responses, we perceive that Meinian Onehealth’s latest move reflects not only a precise grasp of industry development trends but also a response to the corporate responsibility expected of a leading enterprise in its niche sector.

The industry is undergoing dramatic transformation.

One of the transformations lies in the upgrading of health demands. In the past, customers’ health needs were typically focused on disease treatment. However, in recent years, with heightened health awareness and the deepening application of technological innovations such as wearable devices, the concept of proactive health management has been gaining momentum, further driving the prosperity of the health consumption market.

According to the "Report on Development Trends in Health Industry Consumption" released by the China Consumers Association, the total revenue of China’s big health industry is projected to reach 9 trillion yuan in 2024. Behind the robust demand for health consumption lies a fundamental shift: health needs have transitioned from disease treatment to daily health management, thereby raising more profound requirements for corporate products and services.

Take health checkups as an example. Constrained by cost and other factors, a customer’s journey with a health checkup provider often ends at report interpretation and brief consultations on health issues. The provider lacks the means to intervene in detected problems, let alone deliver systematic health management. However, a customer’s health journey does not end with the completion of the checkup. They expect the provider to offer intervention plans for any identified issues. Moreover, with the growing trend toward integrating health management into daily life and making it a routine practice, even customers without abnormal findings have needs for ongoing, everyday health management.

In this regard,Meinian Onehealth embarked on its transformation and upgrade journey from health checkups to comprehensive, full-cycle health management years ago, proposing the holistic, closed-loop service concept of “Two Hours for Checkup, 365 Days of Service.”

The implementation of these services is also linked to Meinian Onehealth’s emphasis on the application of AI technology.

From Yu Rong’s perspective, the application of AI technology can not only enhance the efficiency of medical services and reduce costs, but also improve healthcare quality and optimize service experiences. This approach addresses the “impossible triangle” of healthcare while genuinely advancing the realization of inclusive healthcare. Accordingly, in 2024, Meinian Onehealth formally proposed its “ALL in AI” development strategy.

Therefore, Meinian Onehealth’s comprehensive, closed-loop health management services have incorporated a new element—digital intelligence. Consequently, its development goal for the next decade has evolved from being the leader in the health examination industry to becoming the pioneer in the era of digital-intelligent health management.

Meinian Onehealth’s digital and intelligent health management services span the entire process, including pre-examination, during-examination, and post-examination stages.

During the pre-examination phase, the intelligent agent conducts a smart analysis of the client and provides personalized health checkup packages based on the results. This addresses clients’ confusion and difficulty in choosing among numerous examination items, while also enabling precise screening for potential health issues to a certain extent.

The in-examination and post-examination phases are the “centerpiece” of Meinian Onehealth’s exploration of AI applications. During these phases (including post-examination health management), Meinian Onehealth has launched multiple “specialized, refined, distinctive, and innovative” products aimed at enhancing examination efficiency and accuracy.

For example, in the field of brain science, Meinian Onehealth has launched “Nao Rui Jia,” a precision screening product. Based on specialized MRI examinations, scales, genetic testing, and blood tests, it comprehensively analyzes over 30 dimensions, including genetics, molecular metabolism, brain structural imaging, behavior, emotion, and lifestyle. By employing quantitative analysis of more than 100 brain regions and plaque stability assessment techniques, the product can calculate the 10-year risk of cognitive impairment and the 10-year risk of stroke.

Meinian Onehealth’s magnetically controlled capsule gastroscopy system consists of a capsule endoscope, a cruise capsule endoscope control device, a capsule detector, and a portable recorder. It features painlessness, non-invasiveness, no need for anesthesia, and no risk of cross-infection, and has received awards such as the “Top Ten Medical Advances in China Award” and the “Most Clinically Valuable Innovative Medical Device Award.”

Based on the current AI practices implemented by Meinian Onehealth during the examination phase, its primary objectives appear to be optimizing the testing experience and reducing patient discomfort, as well as enhancing testing efficiency and accuracy. Whether improving testing comfort or boosting testing efficiency and accuracy, these advancements are crucial for the subsequent delivery of health management services.

In the post-examination phase, specifically during out-of-hospital management services, Meinian Onehealth launched China’s first AI-powered digital health manager, “Health Xiaomei,” in 2024. Leveraging large model technology, extensive medical knowledge, and high-quality big data, this initiative aims to provide customers with personalized, diversified, intelligent, and lean whole-lifecycle health management services.

In accordance with standard procedures, during the post-examination phase, Meinian Onehealth provides customers with intelligent interpretation services for their medical checkup reports. Subsequently, based on the health status indicated in the reports, “Health Xiao Mei” matches each customer with corresponding AI agents to deliver systematic health management services. Building on this foundation, Meinian Onehealth also offers tailored intervention products to manage users’ health risks, enabling them to enjoy a healthy lifestyle.

Thus, we have gained insight into the primary reason for Meinian Onehealth’s participation in the Health Growth Alliance: to connect with more high-quality product resources and provide the public with superior, more comprehensive, and diversified health management services. Meanwhile, as an industry leader, Meinian Onehealth has also recognized a significant shift within the sector and has decided to assume the responsibility and mission of guiding the industry’s development.

“The out-of-hospital market is projected to reach a scale of RMB 1.6 trillion by 2029, matching or even surpassing the in-hospital market.” Data from Menet indicates that, driven by strong health demands and compounded by factors such as centralized procurement, China’s out-of-hospital market is experiencing explosive growth.

It has attracted a wave of enterprises to transform, seeking survival and even business growth in the out-of-hospital market. However, according to Wang Rui, Secretary-General of the Health Growth Society, although the out-of-hospital market is booming, it is not easy to penetrate. The difficulties stem from information asymmetry between enterprises and new channels, insufficient precision in understanding user needs, and inadequate cognition of new markets and strategies. In short, enterprises entering the out-of-hospital market need to bridge the gaps in information and resources. This is precisely why the Health Growth Society was founded.

andAs a participating member of the Health Growth Society, Meinian Onehealth will provide enterprises with the following empowerment:

First, as previously stated, Meinian Onehealth has established a closed-loop business model integrating physical examinations with health management. The physical examination segment facilitates the practical application of high-quality diagnostic and testing products, while the health management segment provides application scenarios for premium general health products, intervention protocols, and even wearable devices.

Secondly, Meinian Onehealth can provide enterprises with channels to reach a vast customer base.As of December 31, 2024, Meinian Onehealth has established a network of 576 health examination centers across 296 cities in China, serving 30 million customers annually. Furthermore, since its initial public offering in 2015, Meinian Onehealth has cumulatively provided professional health examination services to 260 million individuals.

Finally, Meinian Onehealth has also accumulated health big data resources on a scale of hundreds of millions, which can empower the research and development of related products.

As for how the Health Growth Society will empower enterprises to develop in the out-of-hospital market, Yu Rong stated that while the society’s vision is ambitious, its practical implementation remains grounded.In the coming period, Health Growth Society will focus on critical issues within key scenarios, precisely matching high-quality solutions with appropriate channels to serve as an accelerator for the commercialization journey of premium products from “1 to 10.”

For instance, in the area of physical examinations, Meinian Onehealth will continue to seek out high-quality disease screening solutions, including early screening for colorectal cancer. In terms of post-examination health management, on one hand, Meinian Onehealth will continue to explore premium health management products, such as those targeting the three major types of nodules, as well as precision nutrition products; on the other hand, the company is actively promoting the application and development of wearable devices, anticipating the emergence of the next blockbuster hit product.

andRecently, Health Growth Society launched its first workshop on practical case studies in business growth.If you offer products in the broad health sector, possess differentiated technological barriers and a mature commercialization pathway, and are committed to building health solutions within preventive medicine scenarios, please scan the QR code below to submit your registration. The Health Growth Society will review your application, and eligible candidates will receive an invitation to attend.

By attending, you will not only gain insights into Meinian Onehealth’s strategic overview of the out-of-hospital market, as well as a breakdown of the top-level strategy and practical implementation pathways for its flagship products, but also have the opportunity to leverage Meinian Onehealth’s out-of-hospital market channels and access valuable channel resources provided by the Health Growth Society.

On June 20, see you at the “Healthy Growth Society Practical Workshop”—we’ll be there!